Treatment of her2 positive cancers
AssigneeSeagen Inc.
InventorsScott Peterson, Luke Walker
Life of this patent
Estimating the term…
Abstract
In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.
Claims20
-68. (canceled)
A method for treating a HER2-positive cancer in a subject, the method comprising administering tucatinib and trastuzumab to the subject, wherein:
- the tucatinib is administered in an amount of about 300 mg twice per day;
- and
- the trastuzumab is administered at an amount of about 6 mg to 8 mg per kg of the subject's body weight once every three weeks;
- wherein the HER2-positive cancer is selected from the group consisting of:
- colorectal cancer, gastric cancer, lung cancer, biliary cancer, and esophageal cancer.
Dependencies are inferred from the claim text.